KAI Pharmaceuticals Announces Phase 1 Results of KAI-4169 for the Treatment of ... - Lifescience-online PDF Print
Lifescience-onlineKAI plans to begin recruitment in a Phase 1b study in patients with ESRD and SHPT this quarter. Steven James, President and CEO of KAI, commented, ?

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.